Good morning and welcome to the ZyVersa Therapeutics 2025 Annual Stockholders Meeting. My name is Steven Glover. I'm Chief Executive Officer, President, and Chairman of the Board of ZyVersa Therapeutics. I am pleased that you could join us today. This meeting is being held virtually to enable shareholders and stockholders to attend regardless of their location. As is our custom, we will conduct the business portion of the meeting first and answer questions at the end of the meeting if time permits. Please keep in mind that we are not at the liberty to share any material non-public information. This meeting is officially called to order, and the polls are now open. You may vote online prior to closing of the polls in accordance with the proxy information you received prior to the meeting.
I am pleased to introduce the other members of our board: Robert Fenizio, Chairperson of our Compensation Committee and Member of our Audit Committee, Gregory Freetag, Chairperson of our Audit Committee and Member of our Nominating and Corporate Governance Committee, James Saperstein, Chairperson of our Nominating and Corporate Governance Committee and Member of our Audit and Compensation Committees, and Dr. Minchu Park, who is a member of our Compensation and Nominating and Corporate Governance Committees. I would also like to introduce our management team: Peter Wolf, our Chief Financial Officer and Corporate Secretary, Dr. Pablo Guzmán, Chief Medical Officer, and Karen Cashmere, our Chief Commercial Officer. I will now turn the meeting over to Peter Wolf, who will act as our Secretary of this meeting.
Thanks, Steve. We are joined here today by our independent auditors, CBIZ CPAs, represented by one of the partners, Nina Quarquillo, and our legal counsel, Thompson Hine LLP, represented by one of the partners, Faith Charles. I would like to announce that Marlene Aguilar, a representative of Broadridge Financial Solutions, has been appointed to act as Inspector of Election. Ms. Aguilar's role is to verify the voter qualifications, accept their votes, and to tally the final votes. She has taken the oath of office to execute her duties with strict impartiality. We will now proceed with the formal business of the meeting, following which we will answer questions from stockholders, time permitting. You may submit questions in the designated field on the web portal. I will now turn the meeting over to the Inspector of Election.
Thank you. ZyVersa's Board of Directors fixed April 15, 2025, as the record date for determining stockholders entitled to vote at this meeting. An affidavit has been delivered attesting to the fact that all stockholders of record were sent information about internet availability of proxy materials, and paper copies of the proxy materials were mailed to stockholders who requested them around April 18, 2025. Proxies have been received for 1,446,712 of the 3,619,456 shares of common stock outstanding and entitled to vote as of the record date. This represents approximately 40% of the total outstanding shares and constitutes a quorum for the meeting today. I will now turn the meeting back to Mr. Wolf, who will discuss the proposals for the vote.
Thank you, Marlene. There are five proposals to be considered by our stockholders. Proposal one is election of two Class III directors, Steven C. Glover and Robert G. Fenizio, to hold office for a term of three years until the nominee successor is duly elected and qualified. Proposal two is ratification of the selection of our Audit Committee of CBIZ CPAs as our independent registered public accounting firm for the year ending December 31, 2025. Proposal three is approval of an amendment and restatement of the company's 2022 Omnibus Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 100,000 shares to 382,122 shares.
Proposal four is the approval of issuance of up to 1,637,000 shares of the company's common stock issuable upon the exercise of certain warrants issued in November 2024 to purchase the company's common stock in accordance with NASDAQ Listing Rule 5635(d). Proposal five is approval of the issuance of up to 2,105,265 shares of the company's common stock issuable upon the exercise of certain warrants issued in March 2025 to purchase the company's common stock in accordance with NASDAQ Listing Rule 5635(d). I will now turn the meeting back over to our CEO, Steven Glover.
The polls remain open to vote on each of the five proposals. This is your last call to submit your ballot. Any stockholder who has not yet voted or wishes to change their vote may do so by clicking on the voting button on the web portal and following the instruction provided there. Stockholders who have sent in their proxies or voted via telephone or internet and do not want to change their vote do not need to make any changes at this time. Each share of ZyVersa common stock is entitled to one vote. We will now pause to enable final voting. Now that everyone has had the opportunity to vote, I declare that the polls are closed on all proposals. Our Inspector of Election will now announce the preliminary vote results.
Thank you. The preliminary vote report shows that Proposal One, to elect two nominees to the board, is approved. Proposal Two, to ratify the company's independent public accounting firm, is also approved. Proposal Three, to increase the number of shares of common stock reserved for issuance under the company's Omnibus Equity Incentive Plan, is approved. Proposal Four, to increase the number of shares of common stock issuable upon the exercise of certain warrants issued in November 2024 to purchase the company's common stock, is approved. Proposal Five, to increase the number of shares of common stock issuable upon the exercise of certain warrants issued in March 2025 to purchase the company's common stock, is also approved. ZyVersa CEO will now adjourn the annual meeting and respond to any questions.
Thank you, Marlene. ZyVersa will report the final vote results in a Form 8-K to be filed within four business days. There being no further business, the annual meeting of stockholders of ZyVersa Therapeutics is now adjourned. At this time, we are offering any stockholders in attendance the opportunity to ask questions, bearing in mind that we are not at liberty to share any material non-public information. Please note we will attempt to answer as many questions as time allows. You may submit your questions in the designated field on the web portal. As there are no further questions, this concludes our meeting. Thank you for attending today. We appreciate your continued support.
This now concludes the meeting. Thank you for attending and have a wonderful rest of your day.
The host has ended.